John Goll has more than 25 years of financial experience within the life sciences industry, most recently serving as Insmed’s SVP, Chief Accounting Officer. In this role, he managed most of the financial activities for the company, including accounting, audit, internal controls, tax, treasury, and international finance operations. During his nine years at Insmed, he helped to raise approximately $3.5 billion in capital through secondary offerings, convertible notes, and other debt financing. John has extensive experience in financial management, FP&A, global operations, corporate finance and accounting, global commercial product launches, SEC compliance and financial assessment of business development and M&A opportunities.
Prior to joining Insmed, John served as VP, Corporate Controller at Warner Chilcott, a global, commercial specialty pharmaceuticals company, from May 2005 to February 2014 (upon acquisition by Allergan). At Warner Chilcott, he was responsible for accounting, audit, global financial operations and long-range planning, treasury, and corporate strategy/M&A.
Having started his career in public accounting, John held roles of increasing responsibility in accounting and FP&A in industry. John earned a Bachelor of Accounting degree from The College of New Jersey and a Master of Business Administration with honors in finance from Fairleigh Dickinson University. He is a Certified Public Accountant and serves on the Board of Directors of the Boys & Girls Clubs of Northwest New Jersey (non-profit).
What is John Goll's net worth?
The estimated net worth of John Goll is at least $21.46 thousand as of February 18th, 2026. Goll owns 653 shares of Immunocore stock worth more than $21,463 as of February 24th. This net worth approximation does not reflect any other assets that Goll may own. Learn More about John Goll's net worth.
How do I contact John Goll?
Has John Goll been buying or selling shares of Immunocore?
During the last quarter, John Goll has sold $22,580.30 in Immunocore stock. Most recently, John Goll sold 698 shares of the business's stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a transaction totalling $22,580.30. Following the completion of the sale, the chief accounting officer now directly owns 653 shares of the company's stock, valued at $21,124.55. Learn More on John Goll's trading history.
Who are Immunocore's active insiders?
Are insiders buying or selling shares of Immunocore?
During the last twelve months, Immunocore insiders bought shares 1 times. They purchased a total of 807,338 shares worth more than $23,994,085.36. During the last twelve months, insiders at the sold shares 6 times. They sold a total of 41,869 shares worth more than $1,429,800.39. The most recent insider tranaction occured on February, 18th when CEO Bahija Jallal sold 11,474 shares worth more than $371,183.90. Insiders at Immunocore own 10.4% of the company.
Learn More about insider trades at Immunocore. Information on this page was last updated on 2/18/2026.
